The efficacy and safety of caspofungin in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease and pulmonary fungal infections
10.3760/cma.j.issn.1008-6706.2016.05.024
- VernacularTitle:卡泊芬净治疗慢性阻塞性肺疾病急性加重期合并肺部真菌感染的疗效及安全性分析
- Author:
Youlin ZHANG
;
Meng TANG
- Publication Type:Journal Article
- Keywords:
Caspofungin;
Pulmonary disease,chronic obstructive;
Pulmonary fungal infections;
Security
- From:
Chinese Journal of Primary Medicine and Pharmacy
2016;23(5):730-733
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study and analyze the efficacy and safety of caspofungin in the treatment of acute exacerbation of chronic obstructive pulmonary disease patients complicated with pulmonary fungal infections.Methods 62 patients of acute exacerbation of chronic obstructive pulmonary disease complicated with pulmonary fungal infec-tions were randomly divided into study group and control group,31 cases in each group.Study group was intravenously given caspofungin,with an initial dose of 70mg/d,follow 50mg/d.The control group was intravenously given liposomal amphotericin B,dose control in 3mg? kg-1 ? d-1 .After treatment lasted symptoms 5d,clinical efficacy and side effects of two groups were recorded.Results The effective rate of the study group was 67.74%,which was signifi-cantly higher than 41.93% of the control group, the difference was statistically significant ( χ2 =2.0251, P =0.0429).The incidence rate of adverse reactions of the study group was 16.13%,which was significantly lower than 48.39% of the control group,the difference was statistically significant(χ2 =2.6948,P =0.0070).After treatment, liver and kidney function parameters in the control group such as ALT,AST,BUN,Cr had significant differences com-pared with before treatment (P <0.05).Conclusion For chronic obstructive pulmonary disease patients complicated with acute exacerbation of pulmonary fungal infection,the treatment efficacy and the incidence of adverse reactions of caspofungin therapy are significantly better than liposomal amphotericin B,and has small renal damage,which is wor-thy of clinical application.
